Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis
End-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S. Food and Drug Administration (FDA)-approved antiviral agent for the treatment of COVID-19 in hospitalized adult and pediatric patients,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-09-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/23247096231200386 |
| _version_ | 1797678142318444544 |
|---|---|
| author | Ryan Geffin MD Shazia Raheem PharmD Lavannya M. Pandit MD, MS Andrew S. Hunter PharmD Michael W. Holliday MD, PhD Aditya V. Rao Maulin K. Shah MD |
| author_facet | Ryan Geffin MD Shazia Raheem PharmD Lavannya M. Pandit MD, MS Andrew S. Hunter PharmD Michael W. Holliday MD, PhD Aditya V. Rao Maulin K. Shah MD |
| author_sort | Ryan Geffin MD |
| collection | DOAJ |
| description | End-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S. Food and Drug Administration (FDA)-approved antiviral agent for the treatment of COVID-19 in hospitalized adult and pediatric patients, though a lack of data has prevented its use in patients with severe kidney disease including dialysis patients. Some observational studies report the use of remdesivir in hemodialysis patients, but there are no reports of patients treated with remdesivir on peritoneal dialysis. Dialysis modalities may affect drug pharmacokinetics, and safety and efficiency of remdesivir in peritoneal dialysis is unknown. We report the first case, to our knowledge, of using remdesivir in a patient treated with peritoneal dialysis with no significant adverse events. This case illustrates the potential for remdesivir to be considered in peritoneal dialysis patients with severe COVID infection. Proper risk analysis and careful monitoring should be done, given the unpredictable clearance of the drug. |
| first_indexed | 2024-03-11T22:55:22Z |
| format | Article |
| id | doaj.art-246067835b924340a7d4331fb62b66e6 |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-03-11T22:55:22Z |
| publishDate | 2023-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-246067835b924340a7d4331fb62b66e62023-09-21T17:03:43ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962023-09-011110.1177/23247096231200386Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal DialysisRyan Geffin MD0Shazia Raheem PharmD1Lavannya M. Pandit MD, MS2Andrew S. Hunter PharmD3Michael W. Holliday MD, PhD4Aditya V. Rao5Maulin K. Shah MD6Baylor College of Medicine, Houston, TX, USAMichael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USAMichael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USAUCHealth Northern Colorado, Fort Collins, CO, USAMichael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USAThe Texas Heart Institute, Houston, TX, USAMichael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USAEnd-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S. Food and Drug Administration (FDA)-approved antiviral agent for the treatment of COVID-19 in hospitalized adult and pediatric patients, though a lack of data has prevented its use in patients with severe kidney disease including dialysis patients. Some observational studies report the use of remdesivir in hemodialysis patients, but there are no reports of patients treated with remdesivir on peritoneal dialysis. Dialysis modalities may affect drug pharmacokinetics, and safety and efficiency of remdesivir in peritoneal dialysis is unknown. We report the first case, to our knowledge, of using remdesivir in a patient treated with peritoneal dialysis with no significant adverse events. This case illustrates the potential for remdesivir to be considered in peritoneal dialysis patients with severe COVID infection. Proper risk analysis and careful monitoring should be done, given the unpredictable clearance of the drug.https://doi.org/10.1177/23247096231200386 |
| spellingShingle | Ryan Geffin MD Shazia Raheem PharmD Lavannya M. Pandit MD, MS Andrew S. Hunter PharmD Michael W. Holliday MD, PhD Aditya V. Rao Maulin K. Shah MD Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis Journal of Investigative Medicine High Impact Case Reports |
| title | Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis |
| title_full | Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis |
| title_fullStr | Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis |
| title_full_unstemmed | Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis |
| title_short | Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis |
| title_sort | treatment of severe covid 19 infection with remdesivir in peritoneal dialysis |
| url | https://doi.org/10.1177/23247096231200386 |
| work_keys_str_mv | AT ryangeffinmd treatmentofseverecovid19infectionwithremdesivirinperitonealdialysis AT shaziaraheempharmd treatmentofseverecovid19infectionwithremdesivirinperitonealdialysis AT lavannyampanditmdms treatmentofseverecovid19infectionwithremdesivirinperitonealdialysis AT andrewshunterpharmd treatmentofseverecovid19infectionwithremdesivirinperitonealdialysis AT michaelwhollidaymdphd treatmentofseverecovid19infectionwithremdesivirinperitonealdialysis AT adityavrao treatmentofseverecovid19infectionwithremdesivirinperitonealdialysis AT maulinkshahmd treatmentofseverecovid19infectionwithremdesivirinperitonealdialysis |